Press Room

4th APV Continuous Manufacturing Conference

Start
Tuesday, May 09, 2023 - 09:00
End
Thursday, May 11, 2023 - 17:00
Location: Lisbon, Portugal
Hovione Lumiar Buildings R and S - aerial view

Hovione will be present and sponsor (gold sponsors) the 4th APV Continuous Manufacturing Conference from May 9-11. Don’t miss the chance to meet with our experts and learn more about the future of continuous manufacturing and how continuous tableting is right for your product. Hovione´s pragmatic approach to bridging science with manufacturing is now being leveraged for continuous tableting and it is the key to ultimately providing high quality medicines and the success of your drug product.

 

HOVIONE PRESENTATIONS

Tuesday, 09 May 2023 | Session 1: Manufacturing experience

A Roadmap to establish continuous tableting as a mainstream industrial platform
José Luís Santos - R&D Director - CoE Continuous Tableting

Tuesday, 09 May 2023 | Session 2: Process control

Control strategies for robust continuous manufacturing of oral dosage forms
Anthony Tantuccio - Fellow Scientist, Corporate Continuous Man. Project

Wednesday, 10 May 2023 | Session 4: Novel CM approaches

Enabling direct compression of amorphous solid dispersions
João Henriques - R&D Senior Manager, Formulation Development

 

The conference will be held in Lisbon - Portugal and includes a visit to our two sites: Hovione Lumiar and Hovione Loures.

 

Learn more about Continuous Tableting at Hovione

 

 

Also in the Press Room

See All

Integrated approach simplifies development, reduces risk, and supports scalable manufacturing. Hovione and Industrial Design Consultancy Ltd.’s (IDC) lead single-use nasal dry powder device is now available for commercial partnerships. Hovione and IDC have completed the device design and established initial device manufacturing and supply capability, enabling pharmaceutical partners to leverage existing capsule filling infrastructure. This approach simplifies development, reduces cost and risk, and helps shorten timelines to the clinic and commercialization. “This milestone marks an important step in the evolution of our collaboration with IDC — from device innovation to a fully integrated intranasal drug delivery platform,” said Márcio Temtem, Ph.D., Vice President, Strategic Business Management, Hovione. “As the industry looks for faster, more reliable ways to bring complex therapies to patients, integration becomes critical. By bringing together nasal particle engineering science, formulation manufacturing and filling, and device technologies into a single offering, we enable a more seamless and predictable development journey, accelerating the path to market for intranasal therapies.” The nasal delivery device enables broad and targeted nasal deposition flexibility while delivering maximum usability and reliability. With a patented design and manufacturing process established, the platform is available for partnering with pharmaceutical companies on an exclusive basis as part of Hovione’s integrated offering for inhalation and nasal drug development and manufacturing. Additionally, IDC’s Managing Director, Stephen Knowles Ph.D., said the companies are now “well-advanced” with the development of a multi-use device to support an even wider range of therapies and patient needs. Read the full article at ContractPharma.com    

Press Clipping

Hovione, IDC Launch Intranasal Drug Delivery Platform

May 07, 2026